Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Dec;48(6):783–790. doi: 10.1038/bjc.1983.267

Concanavalin A induced suppressor cell activity and autorosette forming cells in chronic myeloid leukemia patients.

R Somasundaram, S H Advani, S G Gangal
PMCID: PMC2011565  PMID: 6228243

Abstract

In the present paper attempts have been made to investigate suppressor cell activity in CML patients in first and subsequent remissions in order to study the relationship between suppressor cell activity and progression of the disease. For this purpose, the ability of Con A activated suppressor cells from peripheral blood of CML patients in 1st, 2nd and 3rd remission to suppress PHA response of autologous lymphocytes is investigated and compared with that of normal healthy donors. The ability of Con A activated cell population to form rosettes with autologous RBCs (ARFC) is also investigated. The results indicate that lymphocytes from CML patients in 1st (61.8 +/- 6.1%), 2nd (62.6 +/- 3.0%) and 3rd (55.3 +/- 4.8%) remissions show significantly high suppressor cell activity than normal healthy donors (36.5 +/- 1.9%) when activated with Con A. Similarly, generation of spontaneous suppressor cell activity was also higher in 1st (23.3 +/- 4.7%) and 2nd (25.3 +/- 4.2%) remission lymphocytes than controls (10.1 +/- 2.5%). In the 3rd remission however, the spontaneous suppressor cell activity (14.5 +/- 3.2%) was comparable to controls. Thus it appears that a higher suppressor cell precursor population is present in CML patients in remission. However, this could not be correlated with the progression of the disease. CML patients in 1st remission also revealed an increased percentage of ARFC which correlated with the suppressor cell function. The ARFC activity tested in a few patients in subsequent remissions was comparable with controls although functional suppressor activity was increased.

Full text

PDF
783

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Broder S., Waldmann T. A. The suppressor-cell network in cancer (second of two parts). N Engl J Med. 1978 Dec 14;299(24):1335–1341. doi: 10.1056/NEJM197812142992404. [DOI] [PubMed] [Google Scholar]
  2. Burns F. D., Marrack P. C., Kappler J. W., Janeway C. A., Jr Functional heterogeneity among the T-derived lymphocytes of the mouse. IV. Nature of spontaneously induced suppressor cells. J Immunol. 1975 Apr;114(4):1345–1347. [PubMed] [Google Scholar]
  3. Catalona W. J., Ratliff T. L., McCool R. E. Concanavalin A-activated suppressor cell activity in peripheral blood lymphocytes of urologic cancer patients. J Natl Cancer Inst. 1980 Sep;65(3):553–557. [PubMed] [Google Scholar]
  4. Catalona W. J., Ratliff T. L., McCool R. E. Concanavalin A-inducible suppressor cells in regional lymph nodes of cancer patients. Cancer Res. 1979 Nov;39(11):4372–4377. [PubMed] [Google Scholar]
  5. Gangal S. G., Damle N. K., Khare A. G., Advani S. H. Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens. Br J Cancer. 1979 Sep;40(3):391–396. doi: 10.1038/bjc.1979.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gangal S. G., Gothoskar B. P., Joshi C. S., Advani S. H. Demonstration of cellular immunity in chronic myeloid leukaemia using leucocyte migration inhibition assay. Br J Cancer. 1976 Mar;33(3):267–272. doi: 10.1038/bjc.1976.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gangal S. G., Joshi C. S., Gothoskar B. P., Gollerkeri M. P., Advani S. H. Evaluation of leukemia specific immunity in chronic myeloid leukemia. Haematologica. 1977 Oct;62(5):469–478. [PubMed] [Google Scholar]
  8. Hersh E. M., Patt Y. Z., Murphy S. G., Dicke K., Zander A., Adegbite M., Goldman R. Radiosensitive, thymic hormone-sensitive peripheral blood suppressor cell activity in cancer patients. Cancer Res. 1980 Sep;40(9):3134–3140. [PubMed] [Google Scholar]
  9. Khare A. G., Advani S. H., Gangal S. G. In vitro generation of lymphocytotoxicity to autochthonous leukaemic cells in chronic myeloid leukaemia. Br J Cancer. 1981 Jan;43(1):13–18. doi: 10.1038/bjc.1981.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Naor D. Suppressor cells: permitters and promoters of malignancy? Adv Cancer Res. 1979;29:45–125. doi: 10.1016/s0065-230x(08)60846-5. [DOI] [PubMed] [Google Scholar]
  11. Sakane T., Green I. Human suppressor T cells induced by concanavalin A: suppressor T cells belong to distinctive T cell subclasses. J Immunol. 1977 Sep;119(3):1169–1178. [PubMed] [Google Scholar]
  12. Sakane T., Honda M., Taniguchi Y., Kotani H. Separation of concanavalin A-induced human suppressor and helper T cells by the autologous erythrocyte rosette technique. J Clin Invest. 1981 Aug;68(2):447–453. doi: 10.1172/JCI110274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sakane T., Takada S., Murakawa Y., Kotani H., Honda M., Ueda Y. Analysis of suppressor T cell function in patients with rheumatoid arthritis: defects in production of and responsiveness to concanavalin A-induced suppressor T cells. J Immunol. 1982 Nov;129(5):1972–1977. [PubMed] [Google Scholar]
  14. Schulof R. S., Lee B. J., Lacher M. J., Straus D. J., Clarkson B. D., Good R. A., Gupta S. Concanavalin A-induced suppressor cell activity in Hodgkin's disease. Clin Immunol Immunopathol. 1980 Aug;16(4):454–462. doi: 10.1016/0090-1229(80)90187-7. [DOI] [PubMed] [Google Scholar]
  15. Shou L., Schwartz S. A., Good R. A. Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors. J Exp Med. 1976 May 1;143(5):1100–1110. doi: 10.1084/jem.143.5.1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Toge T., Yanagawa E., Nakanishi K., Yamada Y., Niimoto M., Hattori T. Concanavalin A-activated suppressor cell activity in gastric cancer patients. Gan. 1980 Dec;71(6):784–789. [PubMed] [Google Scholar]
  17. Tsokos G. C., Balow J. E. Suppressor T cells in systemic lupus erythematosus: lack of defective in vitro suppressor cell generation in patients with active disease. J Clin Lab Immunol. 1982 Jun;8(2):83–90. [PubMed] [Google Scholar]
  18. Yu A., Watts H., Jaffe N., Parkman R. Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. N Engl J Med. 1977 Jul 21;297(3):121–127. doi: 10.1056/NEJM197707212970301. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES